Newamsterdam Pharma Company N.V. (NAMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 29,111 | 2,279 | 1,401 | 803 | 2,941 |
| Gross Profit | 29,111 | 2,279 | 1,401 | 803 | 2,941 |
| Operating Expenses | 54,114 | 54,854 | 56,883 | 51,877 | 52,499 |
| Operating Income | -25,003 | -52,575 | -55,482 | -51,074 | -49,558 |
| Other Income | 8,355 | 13,568 | -38,285 | 1,606 | 2,425 |
| Pre-tax Income | -16,648 | -39,007 | -93,767 | -49,468 | -47,133 |
| Income Tax | -1 | N/A | N/A | N/A | N/A |
| Net Income Continuous | -16,647 | -39,007 | -93,767 | -49,495 | -47,133 |
| Net Income | $-16,647 | $-39,007 | $-93,767 | $-49,495 | $-47,133 |
| EPS Basic Total Ops | -0.18 | -0.41 | -1.06 | -0.60 | -0.57 |
| EPS Basic Continuous Ops | -0.18 | -0.41 | -1.06 | -0.60 | -0.57 |
| EPS Diluted Total Ops | -0.18 | -0.41 | -1.06 | -0.60 | -0.57 |
| EPS Diluted Continuous Ops | -0.18 | -0.41 | -1.06 | -0.60 | -0.57 |
| EPS Diluted Before Non-Recurring Items | -0.18 | -0.51 | -0.62 | N/A | N/A |
| EBITDA(a) | $-24,975 | $-52,556 | $-55,467 | $-51,061 | $-49,544 |